Lupus Erythematosus (SLE) and Lupus
Conditions
Interventions
one blood sample of 150 ml will be taken.
Sponsors
Ermium Therapeutics
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • SLE diagnosis according to ACR criteria (for SLE patients) or volunteer in good health • Able to read and und understand an informed consent form written in Dutch • Willing to provide a blood sample • Age > 18 years with no upper age limit • Agree to comply with all study procedures and requirements.
Exclusion criteria
Exclusion criteria: • Unable to undergo blood sample collection • Blood transfusion or donation within 3 months prior to signing ICF • Participation in any other (interventional) study within 3 months prior to signing ICF • If female of childbearing potential, must not be pregnant or lactating • Any condition that in the opinion of the Investigator should preclude participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - investigate the immune system to support the discovery and development of new molecules for the potential treatment of SLE and other autoimmune diseases - to evaluate the effect in vitro of these new molecules on the dysregulated immune system. . | — |
Countries
Netherlands
Outcome results
None listed